Intellia cuts 27% of workforce as it eyes commercial launch
Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development ...
Gene editing stocks drop as Intellia announces layoffs
Shares of gene editing companies dropped on Friday as Wall Street reacted to Intellia Therapeutics' (NASDAQ:NTLA) plans to ...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass, Jan. 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on ...
Why Is Intellia Therapeutics Stock Trading Lower On Friday?
Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of ...
Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo
Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $60 from $70 and keeps an Overweight rating on ...
Strategic Focus and Financial Resilience: Terence Flynn’s Positive Outlook on Intellia Therapeutics
Analyst Terence Flynn of Morgan Stanley maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report), retaining the price target ...
FierceBiotech1d
Intellia, citing 'challenging market environment,' lays off 27% of staff as it takes ax to pipeline
Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce
Ark Invest, led by Cathie Wood, made significant trades in 5 companies on Friday: RXRX, ILMN, NTLA, NET, and ADPT.
STAT1d
Intellia cuts 27% of staff, in the latest wave of gene-editing layoffs
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Intellia Therapeutics (NTLA) Receives a Buy from Evercore ISI
Evercore ISI analyst Liisa Bayko maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price target of ...
Peering Into Intellia Therapeutics's Recent Short Interest
According to Benzinga Pro, Intellia Therapeutics's peer group average for short interest as a percentage of float is 14.00%, which means the company has more short interest than most of its peers. Did ...
Intellia to cut 27% of workforce, discontinue NTLA-3001
Intellia (NTLA) said it plans to focus on developing NTLA-2002 and nex-z and discontinue development of NTLA-3001, which will result in the company cutting 27% of its workforce.